Suven Life Sciences is presenting several data presentations from their portfolio of investigational neuroscience new chemical entities (NCEs) at SFN 2009 from 19 to 21 October held at Chicago, USA. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 34 thousand Neuro Scientists from all over the world covering all the major pharma, biotech and research institutes.
Six senior scientists from Suven are presenting new data from their preclinical and clinical portfolio in four promising areas of neuroscience viz. Alzheimer's, schizophrenia, cognition and major depressive disorders. These areas present significant unmet medical need for which current treatment options are insufficient and address a market size of more than US$ 20 billion. Suven has a number of programmes in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients.
During SFN-2009 Suven lined up with several face to face meetings with major pharma and biotech companies to explore integrated collaborative research programmes (CRP) and also Drug Discovery and Development Support Services (DDDSS). Suven is also discussing with four global pharma majors for licensing and development of their clinical candidate SUVN-502.
Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven's discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven's CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, schizophrenia, depression, cognitive disorders, sleep, neurodegeneration and obesity through CNS targets.